瑞典InfCareHIV队列研究始于2003年，旨在确保对生活中带有艾滋病毒（PLHIV）的人提供平等和有效的护理，并进行长期随访。InfCareHIV作为决策支持系统和质量登记表，确保实时报告最新数据。InfCareHIV包括了瑞典所有诊断艾滋病毒感染的人口的超过99％的数据，到目前为止，已有13,029人列入队列研究。InfCareHIV包括关于HIV相关生物标志物和抗逆转录病毒治疗（ART）的数据，以及关于人口统计学、患者报告的结果和患者报告的经验数据。2015年，瑞典成为首个实现联合国规划厅/世界卫生组织90-90-90目标的国家。晚期诊断艾滋病毒感染被认为是瑞典艾滋病毒流行病的一个关键问题，而在ART治疗时具有低水平HIV病毒血症与全因死亡率相关。在PLHIV中，尽管病毒负载得到抑制，脑脊液中的HIV RNA载量仍增加，这种现象被称为“脑脊液病毒逃逸”。在携带已有核苷类逆转录酶抗药突变的PLHIV中，达芦卡韦为基础的治疗方案与蛋白酶抑制剂为基础的治疗方案相比表现出非劣性。在InfCareHIV队列中观察到了传染性药物抗性的增加。蛋白酶抑制剂低效并不是因为服药依从性较低。随着HIV感染人群的年龄增长，2型糖尿病和胰岛素抵抗的发生率也很高。尽管使用了ART，与HIV阴性者相比，PLHIV患感染相关癌症以及肺癌的风险增加。PLHIV治疗宫颈癌前病变成功率较低，并且更可能具有目前HPV疫苗中未包含的人类乳头瘤病毒类型。PLHIV自报的性满意度正在改善，并且女性显然比男性更高。InfCareHIV提供了一个独特的基础，用于研究并进一步改善在瑞典PLHIV中的长期治疗结果、合并症管理和与健康相关的生活质量。 ©作者（或其雇主）2023年。在CC BY-NC下允许重新使用。不允许商业再利用。由BMJ出版。

The Swedish InfCareHIV cohort was established in 2003 to ensure equal and effective care of people living with HIV (PLHIV) and enable long-term follow-up. InfCareHIV functions equally as a decision support system as a quality registry, ensuring up-to-date data reported in real time.InfCareHIV includes data on >99% of all people with diagnosed HIV in Sweden and up to now 13 029 have been included in the cohort. InfCareHIV includes data on HIV-related biomarkers and antiretroviral therapies (ART) and also on demographics, patient-reported outcome measures and patient-reported experience measures.Sweden was in 2015 the first country to reach the UNAIDS (United Nations Programme on HIV/AIDS)/WHO's 90-90-90 goals. Late diagnosis of HIV infection was identified as a key problem in the Swedish HIV-epidemic, and low-level HIV viraemia while on ART associated with all-cause mortality. Increased HIV RNA load in the cerebrospinal fluid (CSF) despite suppression of the plasma viral load was found in 5% of PLHIV, a phenomenon referred to as 'CSF viral escape'. Dolutegravir-based treatment in PLHIV with pre-existing nucleoside reverse transcriptase inhibitor-mutations was non-inferior to protease inhibitor-based regimens. An increase of transmitted drug resistance was observed in the InfCareHIV cohort. Lower efficacy for protease inhibitors was not due to lower adherence to treatment. Incidence of type 2 diabetes and insulin resistance was high in the ageing HIV population. Despite ART, the risk of infection-related cancer as well as lung cancer was increased in PLHIV compared with HIV-negative. PLHIV were less likely successfully treated for cervical precancer and more likely to have human papillomavirus types not included in current HPV vaccines. Self-reported sexual satisfaction in PLHIV is improving and is higher in women than men.InfCareHIV provides a unique base to study and further improve long-term treatment outcomes, comorbidity management and health-related quality of life in people with HIV in Sweden.© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.